Carbon Ion Radiation Therapy for Unresectable Sacral Chordoma

An Analysis of 188 Cases

Reiko Imai, Tadashi Kamada, Nobuhito Araki, Satoshi Abe, Yukihide Iwamoto, Toshihumi Ozaki, Chihiro Kanehira, Mitsunori Kaya, Kazuhisa Takahashi, Hirokazu Chuman, Hirohiko Tsujii, Masazumi Tsuneyoshi, Yoshihiro Nishida, Hiroaki Hiraga, Toru Hiruma, Rikuo Machinami, Akihiko Matsumine, Seiichi Matsumoto, Hideo Morioka, Takehiko Yamaguchi & 1 others Tsukasa Yonemoto

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Purpose To evaluate the results of carbon ion radiation therapy administered to 188 patients with unresectable primary sacral chordomas. Patients and Methods One hundred eighty-eight patients were treated with carbon ion radiation therapy at a single institute between 1996 and 2013 and retrospectively analyzed. The median age was 66 years. The highest proximal invasion reached past S2 level in 137 patients. The median clinical target volume was 345 cm3. One hundred six patients received 67.2 gray equivalents (GyE)/16 fractions (fr), 74 patients received 70.4 GyE/16 fr, 7 patients received 73.6 GyE/16 fr, and 1 patient received 64.0 GyE/16 fr. Results The median follow-up period was 62 months (range, 6.8-147.5 months). Seventy percent of patients were followed for 5 years or until death. The 5-year local control, overall survival, and disease-free survival rates were 77.2%, 81.1%, and 50.3%, respectively. Forty-one patients had a local recurrence. Sex, tumor volume, level of proximal invasion, and irradiated dose were unrelated to local control. There was grade 3 toxicity of the peripheral nerves in 6 patients and grade 4 toxicity of the skin in 2 patients. Ambulation remained in 97% of patients. Conclusions Carbon ion radiation therapy was safe and effective for unresectable chordoma and provided good local control and survival while preserving ambulation.

Original languageEnglish
Pages (from-to)322-327
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume95
Issue number1
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Heavy Ion Radiotherapy
Chordoma
radiation therapy
carbon
ions
toxicity
Walking
grade
Survival
nerves

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Carbon Ion Radiation Therapy for Unresectable Sacral Chordoma : An Analysis of 188 Cases. / Imai, Reiko; Kamada, Tadashi; Araki, Nobuhito; Abe, Satoshi; Iwamoto, Yukihide; Ozaki, Toshihumi; Kanehira, Chihiro; Kaya, Mitsunori; Takahashi, Kazuhisa; Chuman, Hirokazu; Tsujii, Hirohiko; Tsuneyoshi, Masazumi; Nishida, Yoshihiro; Hiraga, Hiroaki; Hiruma, Toru; Machinami, Rikuo; Matsumine, Akihiko; Matsumoto, Seiichi; Morioka, Hideo; Yamaguchi, Takehiko; Yonemoto, Tsukasa.

In: International Journal of Radiation Oncology Biology Physics, Vol. 95, No. 1, 01.05.2016, p. 322-327.

Research output: Contribution to journalArticle

Imai, R, Kamada, T, Araki, N, Abe, S, Iwamoto, Y, Ozaki, T, Kanehira, C, Kaya, M, Takahashi, K, Chuman, H, Tsujii, H, Tsuneyoshi, M, Nishida, Y, Hiraga, H, Hiruma, T, Machinami, R, Matsumine, A, Matsumoto, S, Morioka, H, Yamaguchi, T & Yonemoto, T 2016, 'Carbon Ion Radiation Therapy for Unresectable Sacral Chordoma: An Analysis of 188 Cases', International Journal of Radiation Oncology Biology Physics, vol. 95, no. 1, pp. 322-327. https://doi.org/10.1016/j.ijrobp.2016.02.012
Imai, Reiko ; Kamada, Tadashi ; Araki, Nobuhito ; Abe, Satoshi ; Iwamoto, Yukihide ; Ozaki, Toshihumi ; Kanehira, Chihiro ; Kaya, Mitsunori ; Takahashi, Kazuhisa ; Chuman, Hirokazu ; Tsujii, Hirohiko ; Tsuneyoshi, Masazumi ; Nishida, Yoshihiro ; Hiraga, Hiroaki ; Hiruma, Toru ; Machinami, Rikuo ; Matsumine, Akihiko ; Matsumoto, Seiichi ; Morioka, Hideo ; Yamaguchi, Takehiko ; Yonemoto, Tsukasa. / Carbon Ion Radiation Therapy for Unresectable Sacral Chordoma : An Analysis of 188 Cases. In: International Journal of Radiation Oncology Biology Physics. 2016 ; Vol. 95, No. 1. pp. 322-327.
@article{e0925601512748e1baf73bfb071dc5df,
title = "Carbon Ion Radiation Therapy for Unresectable Sacral Chordoma: An Analysis of 188 Cases",
abstract = "Purpose To evaluate the results of carbon ion radiation therapy administered to 188 patients with unresectable primary sacral chordomas. Patients and Methods One hundred eighty-eight patients were treated with carbon ion radiation therapy at a single institute between 1996 and 2013 and retrospectively analyzed. The median age was 66 years. The highest proximal invasion reached past S2 level in 137 patients. The median clinical target volume was 345 cm3. One hundred six patients received 67.2 gray equivalents (GyE)/16 fractions (fr), 74 patients received 70.4 GyE/16 fr, 7 patients received 73.6 GyE/16 fr, and 1 patient received 64.0 GyE/16 fr. Results The median follow-up period was 62 months (range, 6.8-147.5 months). Seventy percent of patients were followed for 5 years or until death. The 5-year local control, overall survival, and disease-free survival rates were 77.2{\%}, 81.1{\%}, and 50.3{\%}, respectively. Forty-one patients had a local recurrence. Sex, tumor volume, level of proximal invasion, and irradiated dose were unrelated to local control. There was grade 3 toxicity of the peripheral nerves in 6 patients and grade 4 toxicity of the skin in 2 patients. Ambulation remained in 97{\%} of patients. Conclusions Carbon ion radiation therapy was safe and effective for unresectable chordoma and provided good local control and survival while preserving ambulation.",
author = "Reiko Imai and Tadashi Kamada and Nobuhito Araki and Satoshi Abe and Yukihide Iwamoto and Toshihumi Ozaki and Chihiro Kanehira and Mitsunori Kaya and Kazuhisa Takahashi and Hirokazu Chuman and Hirohiko Tsujii and Masazumi Tsuneyoshi and Yoshihiro Nishida and Hiroaki Hiraga and Toru Hiruma and Rikuo Machinami and Akihiko Matsumine and Seiichi Matsumoto and Hideo Morioka and Takehiko Yamaguchi and Tsukasa Yonemoto",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.ijrobp.2016.02.012",
language = "English",
volume = "95",
pages = "322--327",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Carbon Ion Radiation Therapy for Unresectable Sacral Chordoma

T2 - An Analysis of 188 Cases

AU - Imai, Reiko

AU - Kamada, Tadashi

AU - Araki, Nobuhito

AU - Abe, Satoshi

AU - Iwamoto, Yukihide

AU - Ozaki, Toshihumi

AU - Kanehira, Chihiro

AU - Kaya, Mitsunori

AU - Takahashi, Kazuhisa

AU - Chuman, Hirokazu

AU - Tsujii, Hirohiko

AU - Tsuneyoshi, Masazumi

AU - Nishida, Yoshihiro

AU - Hiraga, Hiroaki

AU - Hiruma, Toru

AU - Machinami, Rikuo

AU - Matsumine, Akihiko

AU - Matsumoto, Seiichi

AU - Morioka, Hideo

AU - Yamaguchi, Takehiko

AU - Yonemoto, Tsukasa

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Purpose To evaluate the results of carbon ion radiation therapy administered to 188 patients with unresectable primary sacral chordomas. Patients and Methods One hundred eighty-eight patients were treated with carbon ion radiation therapy at a single institute between 1996 and 2013 and retrospectively analyzed. The median age was 66 years. The highest proximal invasion reached past S2 level in 137 patients. The median clinical target volume was 345 cm3. One hundred six patients received 67.2 gray equivalents (GyE)/16 fractions (fr), 74 patients received 70.4 GyE/16 fr, 7 patients received 73.6 GyE/16 fr, and 1 patient received 64.0 GyE/16 fr. Results The median follow-up period was 62 months (range, 6.8-147.5 months). Seventy percent of patients were followed for 5 years or until death. The 5-year local control, overall survival, and disease-free survival rates were 77.2%, 81.1%, and 50.3%, respectively. Forty-one patients had a local recurrence. Sex, tumor volume, level of proximal invasion, and irradiated dose were unrelated to local control. There was grade 3 toxicity of the peripheral nerves in 6 patients and grade 4 toxicity of the skin in 2 patients. Ambulation remained in 97% of patients. Conclusions Carbon ion radiation therapy was safe and effective for unresectable chordoma and provided good local control and survival while preserving ambulation.

AB - Purpose To evaluate the results of carbon ion radiation therapy administered to 188 patients with unresectable primary sacral chordomas. Patients and Methods One hundred eighty-eight patients were treated with carbon ion radiation therapy at a single institute between 1996 and 2013 and retrospectively analyzed. The median age was 66 years. The highest proximal invasion reached past S2 level in 137 patients. The median clinical target volume was 345 cm3. One hundred six patients received 67.2 gray equivalents (GyE)/16 fractions (fr), 74 patients received 70.4 GyE/16 fr, 7 patients received 73.6 GyE/16 fr, and 1 patient received 64.0 GyE/16 fr. Results The median follow-up period was 62 months (range, 6.8-147.5 months). Seventy percent of patients were followed for 5 years or until death. The 5-year local control, overall survival, and disease-free survival rates were 77.2%, 81.1%, and 50.3%, respectively. Forty-one patients had a local recurrence. Sex, tumor volume, level of proximal invasion, and irradiated dose were unrelated to local control. There was grade 3 toxicity of the peripheral nerves in 6 patients and grade 4 toxicity of the skin in 2 patients. Ambulation remained in 97% of patients. Conclusions Carbon ion radiation therapy was safe and effective for unresectable chordoma and provided good local control and survival while preserving ambulation.

UR - http://www.scopus.com/inward/record.url?scp=84963623571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963623571&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2016.02.012

DO - 10.1016/j.ijrobp.2016.02.012

M3 - Article

VL - 95

SP - 322

EP - 327

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -